


## AMENDMENTS TO THE CLAIMS


The following listing of claims replaces all prior listings of claims presented in the application.

1. (Currently amended) A purified compound having the following formula of Formula

1



1



wherein n is 2 to 6; Q is NH or O;


R<sub>1</sub> is H or piperazine; and

positions 1, 4, 5, and 8 are optionally substituted with halogen, amine, amino, imino,  
carboxylic acid or amide,

and tautomers, stereoisomers, ~~analogs~~, anhydrides, ~~prodrugs~~, and pharmaceutically acceptable salts and solvates thereof,

wherein the compound is isolated from an ascidian.

2. (Currently amended) A purified compound having the following formula:



wherein n is 2 to 6; Q is NH or O; and R<sub>1</sub> is H or piperazine, and ~~tautomers, stereoisomers, analogs, anhydrides, prodrugs, and pharmaceutically acceptable salts and solvates thereof.~~

3. (Withdrawn) A process for the preparation of a compound according to claim 1 which comprises subjecting an ascidian to solvent extraction.

4. (Withdrawn) A process as claimed in claim 3 wherein said ascidian is *Synoicum macroglossum*.

5. (Withdrawn) A process as claimed in claim 3 wherein said extraction comprises extraction in the presence of methanol followed by a dichloromethane:methanol extraction and the extract so obtained is subject to purification.

6. (Withdrawn) A process as claimed in claim 5 wherein said ascidian comprises freeze dried *Synoicum macroglossum*.

7. (Withdrawn) A process as claimed in claim 6 wherein said dichloromethane and methanol are used in a ratio of 1:1.

8. (Withdrawn) A process as claimed in claim 7 wherein after extraction with dichloromethane and methanol, the extract so obtained is partitioned between water and ethyl acetate.

9. (Withdrawn) A process as claimed in claim 8 wherein said water extract is lyophilized and the residue is triturated with methanol.

{W:\03108\0201123-us\01263762.DOC \\\03108\0201123-us\01263762.DOC }

10. (Withdrawn) A process as claimed in claim 5 wherein said purification comprises a Sephadex LH-20 column chromatography.

11. (Previously presented) A pharmaceutical composition comprising as an active ingredient a compound according to claim 1, and a pharmaceutically acceptable carrier, vehicle or excipient.

12. (Previously presented) A pharmaceutical composition comprising as an active ingredient a compound according to claim 2 and a pharmaceutically acceptable carrier, vehicle or excipient.

13. (Previously presented) A composition as claimed in claim 11 wherein said active ingredient is present in an amount of about 78.8  $\mu\text{g}$ .

14. (Previously presented) A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 15 mg to about 480 mg.

15. (Withdrawn) A pharmaceutical composition comprising a first therapeutic agent consisting of a compound according to claim 2 and a second therapeutic agent different from said first therapeutic agent.

16. (Withdrawn) A composition as claimed in claim 15 wherein said second therapeutic agent is selected from alkylating agents, antimetabolites, vinca alkaloids, antibiotics, cytokines, growth factors and non-steroidal anti-inflammatory drugs.

17. (Withdrawn) A method of treating diabetic disorders in a mammal in need thereof wherein the method comprises administration of a compound according to claim 2.

18. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a compound according to claim 2.

19. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 11.

20. (Previously presented) A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 24 mg to about 280 mg.

21. (Previously presented) A composition as claimed in claim 12 wherein said active ingredient is present in an amount of about 78.8  $\mu\text{g}$ .

22. (Previously presented) A composition as claimed in claim 21 wherein the unit dosage of said composition is from about 24 mg to about 280 mg.

23. (Previously presented) A composition as claimed in claim 21 wherein the unit dosage of said composition is from about 15 mg to about 480 mg.

24. (Withdrawn) A process as claimed in claim 4 wherein said extraction comprises extraction in the presence of methanol followed by a dichloromethane:methanol extraction and the extract so obtained is subject to purification.

25. (Withdrawn) A process as claimed in claim 24 wherein said ascidian comprises freeze dried *Synoicum macroglossum*.

26. (Withdrawn) A process as claimed in claim 25 wherein said dichloromethane and methanol are used in a ratio of 1:1.

27. (Withdrawn) A process as claimed in claim 26 wherein after extraction with dichloromethane and methanol, the extract so obtained is partitioned between water and ethyl acetate.

28. (Withdrawn) A process as claimed in claim 27 wherein said water extract is lyophilized and the residue is triturated with methanol.

29. (Withdrawn) A process as claimed in claim 6 wherein said purification comprises a Sephadex LH-20 column chromatography.

30. (Withdrawn) A process as claimed in claim 7 wherein said purification comprises a Sephadex LH-20 column chromatography.

31. (Withdrawn) A process as claimed in claim 8 wherein said purification comprises a Sephadex LH-20 column chromatography.

32. (Withdrawn) A process as claimed in claim 9 wherein said purification comprises a Sephadex LH-20 column chromatography.

33. (Withdrawn) A process as claimed in claim 24 wherein said purification comprises a Sephadex LH-20 column chromatography.

34. (Withdrawn) A process as claimed in claim 25 wherein said purification comprises a Sephadex LH-20 column chromatography.

35. (Withdrawn) A process as claimed in claim 26 wherein said purification comprises a Sephadex LH-20 column chromatography.

36. (Withdrawn) A process as claimed in claim 27 wherein said purification comprises a Sephadex LH-20 column chromatography.

37. (Withdrawn) A process as claimed in claim 28 wherein said purification comprises a Sephadex LH-20 column chromatography.

38. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 12.

39. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 13.

40. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 14.

41. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 15.

42. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 16.

43. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 20.

44. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 21.

45. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 22.

46. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 23.

47. (Withdrawn) A composition as claimed in claim 16, wherein the non-steroidal anti-inflammatory is aspirin.